Want to see ZVSA full AI Analyst Report?
ZVSA Stock Chart & Stats
$0.10
$0.00(0.00%)
At close: 4:00 PM EDT
$0.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.30
Previous CloseN/A
Volume14.00
Average Volume (3M)15.86K
Market Cap
$8.10K
Enterprise Value$2.52M
Total Cash (Recent Filing)$302.66M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume34,695
30 Day Avg. Volume15,857
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap310.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Therapeutic FocusA focused presence in renal and inflammatory disease gives ZyVersa a defined therapeutic direction and concentrates resources on conditions where new treatments may address substantial medical needs. This focus can support clearer development priorities over the next several quarters.
Clinical PipelineThe company has an identifiable drug-development pathway centered on advancing candidates through clinical trials. Progress in this pipeline could create future product opportunities and establish commercial potential, although the assets remain dependent on successful clinical development.
Asset BaseGrowth in total assets provides a broader resource base than in prior periods and may support continued development activity. This is a limited positive because the same balance sheet remains highly stressed, but the expanding asset base is still a constructive underlying change.
Bears Say
No RevenueZero revenue across multiple years confirms that ZyVersa remains pre-commercial and has no demonstrated sales base to fund operations. Until a candidate reaches approval and commercialization, the business must rely on financing or other capital sources to sustain development.
Severe Cash BurnDeeply negative operating and free cash flow indicate that ongoing development consumes substantial cash without internally generated funding. Persistent burn raises the need for additional capital and increases the risk that future financing could dilute existing shareholders.
Stressed Balance SheetRising debt combined with deeply negative equity materially reduces financial flexibility and weakens the company’s ability to absorb setbacks. This capital structure can constrain investment in the pipeline and heighten refinancing, solvency, and dilution pressures.
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.04 and its highest was $0.30 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $8.10K.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 17 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$0.22 in its last earnings report. Following the earnings report the stock price went down -3.883%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―